Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bavituximab + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Avid Bioservices
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bavituximab + paclitaxel is a combination therapy consisting of bavituximab, a chimeric monoclonal antibody that targets phosphatidylserine (PS) on tumor vasculature, and paclitaxel, a microtubule-stabilizing chemotherapeutic agent. Bavituximab binds to PS exposed on the surface of tumor blood vessels under stress conditions such as hypoxia, blocking immunosuppressive signals and promoting antitumor immunity through effects on monocytes and myeloid-derived suppressor cells. It also induces antibody-dependent cellular cytotoxicity against tumor-associated endothelial cells. Paclitaxel disrupts cell division by stabilizing microtubules, leading to apoptosis in rapidly dividing cancer cells. The combination has been investigated in multiple phase I/II clinical trials for advanced solid tumors including metastatic breast cancer, non-small cell lung cancer (NSCLC), and gastric/gastroesophageal junction (GEJ) cancers[1][2][8]. The regimen has shown promising response rates and manageable toxicity profiles.
- Other names
- bavituximab plus paclitaxelbavituximab and paclitaxelbavituximab + taxane
02
Targets
B2GP1 (Beta-2-glycoprotein I)TUBA (Tubulin alpha/beta dimer)
Beyond the preview
Go deeper on bavituximab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bavituximab + paclitaxel.